Rare Side Effects of Valproic Acid: Gingival Hyperplasia, and Cervical Lymphadenopathy

Yıl 2013, Cilt: 15 Sayı: 1, 56 - 57, 01.03.2013

Serhat Demirer Burcu Gökçe Betül Acar Hüseyin Gencal Keçeli Uğur Bahadır Aylıkçı Ali Kemal Erdemoğlu Ersel Dağ

Öz

Gingival hyperplasia is a common disorder seen in patients with epilepsy treated with phenytoin.It is rarely seen in patients taking sodium valproate therapy. Especially in mentally retardedpatients, poor oral hygiene causes to the accumulation of bacterial plaque and inflammationmight be occurs. Connective tissue increases due to inflammation and gingival hyperplasia isseen. We report a case of gingival hyperplasia due to valproic acid use to draw attention to rare adverseeffect of this drug

Anahtar Kelimeler

Valproic acid, gingival hyperplasia, epilepsy

Valproik Asit’in Nadir Yan Etkileri: Gingiva Hiperplazisi Ve Servikal Lenfadenopati

Öz

Dişeti hiperplazisi antiepileptik ilaçlardan fenitoin tedavisi alan epilepsi hastalarında sık görülenbir yan etkidir. Literatürde valproik asit tedavisi alan olgularda gingival hiperplazi çok nadirgözlenen bir yan etki olarak belirtilmiştir. Özellikle mental retardasyonlu hastalarda ağızhijyeninin kötü olması nedeniyle bakteriyel plak birikimi ve inflamasyon meydana gelebilir.İnflamasyona bağlı olarak konnektif dokuda artış ve sonrasında dişeti hiperplazisi görülebilir.Çalışmamızda valproik asit kullanımına bağlı gelişen gingival hiperplazi olgusunu, bu ilacınnadir görülen yan etkilerine dikkat çekmek amacıyla sunuyoruz

Anahtar Kelimeler

Valproik asit, gingiva hiperplazisi, epilepsi

Kaynakça

• Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug induced gingival hyperplasia. J Oral Pathol Med 1991: 20; 201-209.
• Seymor RA, Thomason JM, Ellis JS. The pathogenesis of drug induced gingival overgrowth. J Clin Peridontol 1996; 23: 165- 175.
• Bökenkamp A, Bohnhorst B, Beier C, Albers N, Offner G, Brodehl J. Nifedipine aggravates cyclosporine A-induced Hyperplasi. Pediatr Nephrol 1994; 8:181.
• Seymor RA, Ellis JS, Thomason JM. Risk factor for drug- induced gingival overgrowth. J Clin Peridontol 2000; 27: 217-223.
• Anderson HH, Rapley JW, Williams DR. Gingival overgrowth with valproic acid: a case report.ASDC J Dent Child. 1997;64:294-297.
• Dahllof, G.; Axio, E. & Modeer, T. Regression of phenytoin- induced gingival overgrowth after withdrawal of medication Swedish Dental Journal. 1991;15:139-143.
• Forsberg H, Quick-Nilsson I, Gustavson KH, Jagell S. Dental health and dental care in severely mentally retarded children. Swed Dent J 1985; 9: 15-28.
• R.D. Coletta and E. Graner. “Hereditary gingival fibromatosis: a systematic review,”. 2006; 5: 753–764.
• Albrecht J, Fine LA, Piette W. Drug-associated lymphoma and pseudolymphoma: recognition and management. Dermatol Clin. 2007; 25: 233-244.
• Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol. 1996; 27:125-132.
• Cogrel O, Belot- Barry M, Vergier B, et al. Sodium valproate- induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. British Journal of Dermatology 2001; 144: 1235-1238.